– Announced Positive Topline Results from ONC201 in Recurrent H3 K27M-mutant Glioma –
–U.S. Food and Drug Administration (FDA) Published Article Summarizing Benefit-Risk Assessment of TEMBEXA for the Treatment of Smallpox –
– Conference Call at 8:30 a.m. ET Today –
DURHAM, N.C., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the third quarter ended September 30, 2021 and provided an operational update.
“We are pleased with the progress we have made in 2021 towards advancing our pipeline and validating our imipridone programs. Today, we announced positive topline results from the BICR of the ONC201 50 patient cohort in recurrent H3 K27M-mutant glioma, furthering our conviction that this program has the potential to significantly improve the standard of care for these patients with severe unmet medical need,” said Mike Sherman, Chief Executive Officer of Chimerix. “As we look to the balance of the year, we plan to continue to advance our clinical programs and expect to complete TEMBEXA® manufacturing for initial potential stockpiling in support of U.S. national preparedness.”
Recent Highlights
ONC201 for Recurrent H3 K27M-mutant Glioma
Earlier today, Chimerix reported topline data from the 50-patient cohort of ONC201 for the treatment of recurrent H3 K27M-mutant glioma. ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist for the treatment of recurrent gliomas that harbor the H3 K27M mutation.
According to a blinded independent central review (BICR) of the registration cohort, the overall response rate (ORR) was 20.0% (95% confidence interval (CI):10.0-33.7%) as determined by Response Assessment in Neuro-Oncology Criteria for High Grade Gliomas (RANO-HGG). The median duration of response was 11.2 months (95% CI: 3.8 – not reached) and the median time to response was 8.3 months. Prior review of ONC201 identified the most commonly reported adverse events as nausea/vomiting, fatigue and decreased lymphocyte counts. Additional supportive data, including measures of other forms of clinical benefit and survival analysis will be presented at the Society for Neuro-Oncology (SNO) Annual Meeting November 19-21, 2021.
TEMBEXA for Smallpox
In June, the FDA granted TEMBEXA tablets and oral suspension approval for the treatment of smallpox. TEMBEXA is approved for adult and pediatric patients and is the first and only smallpox therapy approved for neonates. The oral suspension formulation is particularly important for patients who have difficulty swallowing due to age or medical status.
TEMBEXA potentially fills an important role as a treatment countermeasure to smallpox; it has a differentiated mechanism of action, a relatively high barrier to resistance and available evidence suggests it can be used in patients who have received the other FDA approved smallpox antiviral treatment. In September, an article was published in the peer review journal, Antiviral Research, providing a thorough assessment of TEMBEXA as a medical counter measure for smallpox. The article can be accessed here.
By year-end, Chimerix expects to complete initial TEMBEXA drug product manufacturing in order to execute first shipments to the strategic national stockpile in response to a potential procurement contract to support national preparedness in the United States.
DSTAT for AML
Chimerix continues enrollment in the Phase 3 Dociparstat in AML with Standard Chemotherapy (DASH AML) study of DSTAT for the treatment of AML. The multicenter, randomized, double-blind, placebo-controlled, parallel-group study is being conducted to evaluate the efficacy and safety of DSTAT in combination with standard intensive induction and consolidation chemotherapy for the treatment of newly diagnosed AML patients. Chimerix expects to unblind data following enrollment of the first 80 evaluable patients in this study to assess complete response rates and minimal residual disease rates between the study arm and the control arm. To date, enrollment of this study has proceeded more slowly than expected due to hospital staffing shortages related to COVID-19. We expect to complete enrollment of the first 80 evaluable patients in the second half of 2022.
Third Quarter 2021 Financial Results
Chimerix reported a net loss of $18.6 million, or $0.21 per basic and diluted share, for the third quarter of 2021. During the same period in 2020, Chimerix recorded a net loss of $11.4 million, or $0.18 per basic and diluted share.
Revenues for the third quarter of 2021 decreased to $0.1 million, compared to $1.6 million for the same period in 2020.
Research and development expenses increased to $13.8 million for the third quarter of 2021, compared to $10.0 million for the same period in 2020 driven primarily by the expanded pipeline associated with the acquisition of Oncoceutics, Inc in January 2021.
General and administrative expenses increased to $4.9 million for the third quarter of 2021, compared to $3.2 million for the same period in 2020.
Chimerix's balance sheet as of September 30, 2021, included approximately $125 million of capital available to fund operations, $14.0 million in a note payable related to the Oncoceutics transaction and approximately 86.8 million outstanding shares of common stock.
In accordance with the terms of the merger agreement between Chimerix and Oncoceutics, Inc., the achievement of the 20% ORR via BICR will result in a success milestone payment of $20 million to the former Oncoceutics, Inc. shareholders to be paid prior to year-end.
Conference Call and Webcast
Chimerix will host a conference call and live audio webcast to discuss third quarter 2021 financial results and provide a business update today at 8:30 a.m. ET. To access the live conference call, please dial 877-354-4056 (domestic) or 678-809-1043 (international) at least five minutes prior to the start time and refer to conference ID 5935686.
A live audio webcast of the call will also be available on the Investors section of Chimerix’s website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.
About Chimerix
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. In June 2021, the U.S. Food and Drug Administration granted approval of TEMBEXA for the treatment of smallpox as a medical countermeasure. The Company has two other advanced clinical-stage development programs, ONC201 and dociparstat sodium (DSTAT). ONC201 is in development for recurrent H3 K27M-mutant glioma. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia.
About TEMBEXA
TEMBEXA is an oral antiviral formulated as 100 mg tablets and 10 mg/mL oral suspension dosed once weekly for two weeks. TEMBEXA is indicated for the treatment of human smallpox disease caused by variola virus in adult and pediatric patients, including neonates. TEMBEXA is not indicated for the treatment of diseases other than human smallpox disease. The effectiveness of TEMBEXA for the treatment of smallpox disease has not been determined in humans because adequate and well-controlled field trials have not been feasible and inducing smallpox disease in humans to study the drug’s efficacy is not ethical. TEMBEXA efficacy may be reduced in immunocompromised patients based on studies in immune deficient animals.
TEMBEXA (brincidofovir) is a nucleotide analog lipid-conjugate designed to mimic a natural monoacyl phospholipid to achieve effective intracellular concentrations of the active antiviral metabolite, cidofovir diphosphate. Cidofovir diphosphate exerts its orthopoxvirus antiviral effects by acting as an alternate substrate inhibitor for viral DNA synthesis mediated by viral DNA polymerase.
IMPORTANT SAFETY INFORMATION Including BOXED WARNING
| WARNING: INCREASED RISK FOR MORTALITY WHEN USED FOR LONGER DURATION An increased incidence of mortality was seen in TEMBEXA-treated subjects compared to placebo-treated subjects in a 24-week clinical trial when TEMBEXA was evaluated in another disease. |
WARNINGS AND PRECAUTIONS
Elevations in Hepatic Transaminases and Bilirubin: May cause increases in serum transaminases (ALT or AST) and serum bilirubin. Monitor liver laboratory parameters before and during treatment.
Diarrhea and Other Gastrointestinal Adverse Events: Diarrhea and additional gastrointestinal adverse events including nausea, vomiting, and abdominal pain may occur. Monitor patients, provide supportive care, and if necessary, do not give the second and final dose of TEMBEXA.
Coadministration with Related Products: TEMBEXA should not be co-administered with intravenous cidofovir.
Carcinogenicity: TEMBEXA is considered a potential human carcinogen. Do not crush or divide TEMBEXA tablets and avoid direct contact with broken or crushed tablets or oral suspension.
Male Infertility: Based on testicular toxicity in animal studies, TEMBEXA may irreversibly impair fertility in individuals of reproductive potential.
ADVERSE REACTIONS
Common adverse reactions (adverse events assessed as causally related by the investigator in ≥ 2% of subjects) experienced in the first 2 weeks of dosing with TEMBEXA were diarrhea, nausea, vomiting and abdominal pain.
USE IN SPECIFIC POPULATIONS
Pregnancy
Based on findings from animal reproduction studies, TEMBEXA may cause fetal harm when administered to pregnant individuals. Pregnancy testing should be performed before initiation of TEMBEXA in individuals of childbearing potential to inform risk. An alternative therapy should be used to treat smallpox during pregnancy, if feasible.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, results from the BICR of the 50- patient cohort of ONC201 for the treatment of recurrent H3 K27M-mutant glioma, the status of Chimerix’s oncology programs, and the manufacturing, potential benefits and government procurement of TEMBEXA. Among the factors and risks that could cause actual results to differ materially from those indicated in the forward-looking statements are risks that the current clinical study data for ONC201 will not support accelerated, or any, regulatory approval; the anticipated benefits of the acquisition of Oncoceutics may not be realized; the ability to generate positive results in a Phase 3 study in acute myeloid leukemia and subsequent approval for DSTAT; risks that Chimerix will not obtain a procurement contract for TEMBEXA in smallpox in a timely manner or at all; Chimerix’s current BCV manufacturing efforts may not satisfy the requirements of any procurement award; Chimerix’s reliance on a sole source third-party manufacturer for drug supply; risks that ongoing or future trials may not be successful or replicate previous trial results, or may not be predictive of real-world results or of results in subsequent trials; risks and uncertainties relating to competitive products and technological changes that may limit demand for our drugs; risks that our drugs may be precluded from commercialization by the proprietary rights of third parties; and additional risks set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.
CONTACT:
Investor Relations:
Michelle LaSpaluto
919-972-7115
ir@chimerix.com
Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com
| CHIMERIX, INC. | ||||||||||||
| CONSOLIDATED BALANCE SHEETS | ||||||||||||
| (in thousands, except share and per share data) | ||||||||||||
| (unaudited) | ||||||||||||
| September 30, | December 31, | |||||||||||
| 2021 | 2020 | |||||||||||
| ASSETS | ||||||||||||
| Current assets: | ||||||||||||
| Cash and cash equivalents | $ | 26,174 | $ | 46,989 | ||||||||
| Short-term investments, available-for-sale | 96,384 | 31,973 | ||||||||||
| Accounts receivable | 53 | 340 | ||||||||||
| Inventories | 1,595 | - | ||||||||||
| Prepaid expenses and other current assets | 4,327 | 2,356 | ||||||||||
| Total current assets | 128,533 | 81,658 | ||||||||||
| Long-term investments | 2,035 | - | ||||||||||
| Property and equipment, net of accumulated depreciation | 264 | 214 | ||||||||||
| Operating lease right-of-use assets | 2,509 | 2,825 | ||||||||||
| Other long-term assets | 60 | 26 | ||||||||||
| Total assets | $ | 133,401 | $ | 84,723 | ||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||
| Current liabilities: | ||||||||||||
| Accounts payable | $ | 1,792 | $ | 1,283 | ||||||||
| Accrued liabilities | 10,498 | 7,250 | ||||||||||
| Note payable | 14,000 | - | ||||||||||
| Total current liabilities | 26,290 | 8,533 | ||||||||||
| Lease-related obligations | 2,525 | 2,814 | ||||||||||
| Total liabilities | 28,815 | 11,347 | ||||||||||
| Stockholders’ equity: | ||||||||||||
| Preferred stock, $0.001 par value, 10,000,000 shares authorized at September 30, 2021 and | ||||||||||||
| December 31, 2020; no shares issued and outstanding as of September 30, 2021 and | ||||||||||||
| December 31, 2020 | - | - | ||||||||||
| Common stock, $0.001 par value, 200,000,000 shares authorized at September 30, 2021 and | ||||||||||||
| December 31, 2020; 86,848,426 and 62,816,039 shares issued and outstanding as of | ||||||||||||
| September 30, 2021 and December 31, 2020, respectively | 87 | 63 | ||||||||||
| Additional paid-in capital | 950,597 | 785,673 | ||||||||||
| Accumulated other comprehensive loss, net | - | - | ||||||||||
| Accumulated deficit | (846,098 | ) | (712,360 | ) | ||||||||
| Total stockholders’ equity | 104,586 | 73,376 | ||||||||||
| Total liabilities and stockholders’ equity | $ | 133,401 | $ | 84,723 | ||||||||
| CHIMERIX, INC. | |||||||||||||||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | |||||||||||||||||||||
| (in thousands, except share and per share data) | |||||||||||||||||||||
| (unaudited) | |||||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||||||||
| Revenues: | |||||||||||||||||||||
| Contract revenue | $ | 105 | $ | 1,591 | $ | 1,928 | $ | 4,158 | |||||||||||||
| Licensing revenue | 2 | 18 | 5 | 94 | |||||||||||||||||
| Total revenues | 107 | 1,609 | 1,933 | 4,252 | |||||||||||||||||
| Operating expenses: | |||||||||||||||||||||
| Research and development | 13,820 | 10,018 | 39,480 | 27,545 | |||||||||||||||||
| General and administrative | 4,887 | 3,151 | 13,431 | 9,466 | |||||||||||||||||
| Acquired in-process research and development | - | - | 82,890 | - | |||||||||||||||||
| Total operating expenses | 18,707 | 13,169 | 135,801 | 37,011 | |||||||||||||||||
| Loss from operations | (18,600 | ) | (11,560 | ) | (133,868 | ) | (32,759 | ) | |||||||||||||
| Other income: | |||||||||||||||||||||
| Interest income and other, net | 40 | 149 | 130 | 912 | |||||||||||||||||
| Net loss | (18,560 | ) | (11,411 | ) | (133,738 | ) | (31,847 | ) | |||||||||||||
| Other comprehensive loss: | |||||||||||||||||||||
| Unrealized gain (loss) on debt investments, net | 11 | (97 | ) | - | (2 | ) | |||||||||||||||
| Comprehensive loss | $ | (18,549 | ) | $ | (11,508 | ) | $ | (133,738 | ) | $ | (31,849 | ) | |||||||||
| Per share information: | |||||||||||||||||||||
| Net loss, basic and diluted | $ | (0.21 | ) | $ | (0.18 | ) | $ | (1.59 | ) | $ | (0.51 | ) | |||||||||
| Weighted-average shares outstanding, basic and diluted | 86,335,357 | 62,242,456 | 84,277,555 | 62,009,941 | |||||||||||||||||
